US FDA and French regs hit separate Chinese API makers with warnings

By Dan Stanton

- Last updated on GMT

US FDA and French regs hit separate Chinese API makers with warnings

Related tags Food and drug administration

Systemic data manipulation has landed Chinese API maker Zhejiang Hisun Pharmaceutical with a US FDA warning letter.

Following an inspection at the company’s manufacturing facility in Taizhou City, Zhejiang Province, last March, the US Food and Drug Administration (FDA) has issued Zhejiang Hisun a warning citing a number of deviations from current good manufacturing practice (cGMP).

According to the letter​, the firm failed to “prevent unauthorized access or changes to data, and to provide adequate controls to prevent manipulation and omission of data,” ​and instead relied on incomplete records to evaluate the quality of drugs.

Furthermore, the Agency continued: “We observed systemic data manipulation across your facility, including actions taken by multiple analysts, on multiple pieces of testing equipment, and for multiple drugs.”

The API maker was also cited as having deleted original data and disabled the audit trail at the facility.

“Because the audit trail was disabled, neither your quality unit nor your laboratory staff could demonstrate that records for these batches included complete and unaltered data.”

Alongside data issues, the company failed to conduct appropriate microbiological testing on API batches.

“We observed that all 14 culture media plates in incubator #6 were dried out and cracked, which compromised microbial growth promotion and accurate enumeration. These plates were used to test multiple API batches,” the letter said.

Zhejiang Hisun claims, in the letter, that deformed glass plates had caused the media to crack, and the batches were retested.

EU hits another Chinese API maker

The warning is the latest for China’s API industry. This month, the French National Agency for Medicines and Health Products Safety (AFMPS) issued a certificate of non-compliance​ to Minsheng Group ShaoXing Pharmaceutical at its site also in the Zhejiang Province.

“Overall, 18 deficiencies were observed during the inspection, including 2 Critical and 4 Major deficiencies,”​ the certificate said.

These included the falsification of source of API (Thiamphenicol): repackaging, relabeling and selling the purchased API from a non-GMP company (Zhejiang Runkang Pharmaceutical Co.Ltd.) as if manufactured in-house. A lack of audit trail was also cited.

And last April​ the FDA sent cancer-drug API maker Yunnan Hande Bio-Tech a letter after observing data manipulation at its plant in Kunming, Yunnan Province.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us